Endometrial Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer Pipeline Review, H2 2016, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 35, 17, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.Endometrial Cancer.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA